Kiv-318
Phase 1
Kiv-318 is one of 5 therapeutic programs targeting Refractory Multiple Myeloma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1BLENREP
GGlaxo Dba Glaxosmithkline
Phase 2
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Elranatamab
PfizerPhase 2
Kiv-318
IInstitute of Hematology & Blood Diseases Hospital, China
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Refractory Multiple Myeloma1 trial
A Single-arm, Open-label, Multicenter, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KIV-318 Injection in Patients With Relapsed/Refractory Multiple Myeloma.
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07726160·30 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Kiv-318. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]